
Thursday, August 23, 2007 7:13:50 AM
Thursday August 23, 7:00 am ET
SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM - News) announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, 2007 at 3:15 p.m. (Eastern Time) at the Four Seasons Hotel in Boston, Massachusetts.
To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.monogrambio.com.
Contacts: Alfred G. Merriweather
Chief Financial Officer
Tel: 650 624-4576
amerriweather@monogrambio.com
Jeremiah Hall
Feinstein Kean Healthcare
Tel: 415 677-2700
jeremiah.hall@fkhealth.com
Change is the only constant
Recent MGRM News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 01:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2024 09:13:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2024 01:52:37 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:33:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:07:08 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/08/2024 03:00:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/30/2024 07:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 01:28:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2024 09:23:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 09:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 01:35:28 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/11/2024 09:26:27 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:51:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 10:30:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:20:40 PM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 05/08/2024 08:55:25 PM
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups • COEP • Feb 13, 2025 9:10 AM
Unitronix Corp. to Report Over 300% Gains in Cryptocurrency Assets • UTRX • Feb 13, 2025 7:15 AM
Hivello Token ($HVLO) now Live • MATE • Feb 11, 2025 9:27 AM
Animoca Brands leads Hivello funding round ahead of Token Listing • MATEF • Feb 10, 2025 10:20 AM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM